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Apoptosis research enters the ICE age
Recent elucidation of the structure of interleukin-1 [g-converting
enzyme (ICE), a protease with sequence homology to a nematode
protein associated with programmed cell death, opens a new chapter
in the study of how proteases may control cellular suicide.
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Recently, the three-dimensional structure of interleukin-
l-converting enzyme (ICE), the protease responsible
for cleaving IL-l1 from its precursor to mature form,
was solved by two independent groups [1,2]. While this
has drawn significant attention from molecular immunol-
ogists and structural biologists alike, the information has
also attracted the notice of scientists studying the process
of apoptosis (also known as physiological or programmed
cell death) [3]. While ICE plays a crucial role in initiation
of the T-cell response by the immune system, it may also
have a more fundamental role that strikes at the very
heart of how every cell is able to survive. ICE shares 28%
sequence identity with the CED-3 protease, the product
of cell death gene-3 from the nematode Caenorhabditis
elegans [4], a protein known to cause apoptosis. This con-
nection between ICE and CED-3 has sparked intense
interest in these proteases, suggesting that ICE or an
ICE-like homolog may be participating in the complex
cascade that will destine a cell for suicide by apoptosis.
This article presents the molecular players in the field of
apoptosis and gives a brief overview of the current state
of research and future directions.
To live or to die?
Apoptosis is a controlled process by which an individual
cell within an organism is eliminated. (For a recent
review, see [5].) In multicellular organisms, homeostasis is
achieved through a continual balance between cell prolif-
eration, quiescence, differentiation and death, with death
occurring by one of two general pathways: necrosis or
apoptosis. Apoptosis is an active process that allows cell
suicide to occur in an orderly manner without giving rise
to the inflammatory response which is normally charac-
teristic of cell death by necrosis. The apoptotic process is
closely tied to cell proliferation whereby some of the
same molecules that regulate progression through the cell
cycle, such as the proteins myc and p53, can also serve at
checkpoints to regulate whether a cell should initiate
apoptosis [6-8]. The link between the processes of life
(proliferation) and death (apoptosis) results from self-reg-
ulation, perhaps based on the ratio of proliferative and
suicidal signals that are constantly being sensed by the
nucleus of the cell. When signalling between these diver-
gent life and death pathways loses its synchrony, as is the
case in cells that are severely damaged by radiation or
chemotherapeutic agents, the cell may respond with sig-
nals which activate apoptosis. The ability of an individual
cell to recognize that it is too extensively damaged to be
properly repaired would insure that mutated cells could
be eliminated for the overall good of the organism. This
may be an important regulatory mechanism for main-
tenance of homeostasis. Left uncontrolled, mutations
which disrupt the balance between life and death signals
could cause cells to proceed through uncontrolled pro-
liferation [9]. While loss of proliferative control is a
common feature of cancers, an unregulated propensity
for apoptosis may lead to degenerative diseases, such as
Alzheimer's disease [10,11] or AIDS [12].
Recent advances in cell and molecular biology have
modified our views about how both normal and trans-
formed cells live and die. Normal cells are capable of
proliferating for a finite number of cell divisions. In
response to cellular signalling (both from internal and
external stimuli) an individual cell can either become ter-
minally differentiated, become quiescent while awaiting
an external stimulus, or undergo physiological cell death.
It is generally believed that cancer cells possess a growth
advantage that permits them to continue proliferating
without reaching these finite limits. Moreover, it is
becoming clear that some cancer cells also have a 'death
advantage': some tumor cells lose the ability to die by
apoptosis. In solid tumors, cells that escape growth
control and lose responsiveness to signals that would trig-
ger apoptosis contribute to the net accumulation (i.e.
growth) of solid tumor mass.
Molecular basis of apoptosis
While the cellular mechanisms that control apoptosis are
not fully understood, several important genes and their
protein products that are capable of participating in ini-
tiation and progression of the cell death process have
been identified and cloned (Fig. 1). Much of this infor-
mation is based on fundamental research with C. elegans.
The fate of each of the 1090 cells in C. elegans has been
mapped during maturation [13]. Of these, 131 cells are
destined to undergo apoptosis during development.
From studies of these cells and the genes that control
development, Ellis and Horvitz identified ced-3 as critical
for the process of apoptosis [14]. When this gene was
mutated, cells that should have been eliminated during
development remained viable. Studies of C. elegans and
its cell death genes have continued for several years; how-
ever, it was not until 1993 that the relationship between
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Fig. 1. A model for cell death by apop-
tosis. Apoptosis can be triggered in cells
by a variety of factors, including geno-
toxic stress, damage by X-rays, activa-
tion by selected cytokines, or removal
of growth factors. The tumor suppressor
protein, p53, which also controls pro-
gression through the cell cycle, is
thought to control the decision to
undergo apoptosis. Cell death mod-
ulators, such as Bax/Bcl-X s and
Bcl-2/Bcl-X L, act to promote or prevent
cell death, respectively. An ICE-related
protease may be responsible for activa-
tion or propagation of the death signal.
The overall process of cell death
involves overlapping pathways that ulti-
mately result in chromatin condensa-
tion, nuclear disintegration, membrane
blebbing, loss of cell volume and frag-
mentation of the cell into apoptotic
bodies.
the CED-3 protease and the cellular protease ICE was
recognized [4]. While the role of ICE itself as a compo-
nent of the cell death machinery remains controversial,
homology between these two proteins points to a com-
monality of function. Considerable effort has gone into
demonstrating that ICE, like CED-3, is capable of caus-
ing apoptosis [4]. Several other proteins having partial
sequence homology to ICE have been identified and
characterized in the past year [15,16]. Together, these
proteases represent a family of proteins that may be
responsible for a wide variety of both positive and nega-
tive effects on apoptosis.
ICE and its homologs
ICE is a novel cysteine protease that is encoded as an
inactive 45 kDa precursor protein [17]. Through auto-
activation, an inactive dimer is cleaved to an active
heterotetramer consisting of two p20 and two p10O sub-
units. An active-site cysteine residue (Cys285) within the
sequence QACRG is conserved throughout this family
of proteases which cleave target proteins selectively at
aspartyl residues [17]. Important information about the
catalytic mechanism and organization of subunits can be
derived from the X-ray crystal structure of the protein
[1,2]. The mechanism of peptide cleavage involves for-
mation of a tetrahedral intermediate with histidine
(His237), glutamine (Gln283) and arginine (Arg179)
residues providing essential contacts required for substrate
binding and stabilization of the intermediate complex
[1,2]. The organization of the heterotetramer into an
inter-digitated complex is unique among proteases, and
represents a novel quaternary structure. It is thought that
the active site is composed of a p20 and plO subunit
contributed by each precursor, rather than from the same
precursor molecule. This type of organization may have
implications for the control of ICE activation, although
additional studies will be required to clarify the role.
The most recently identified ICE homolog, Ich-1 (ICE
and CED-3 homolog-l), has been shown to exist in two
forms, Ich-1L (long) and Ich-1s (short), as a result of
alternative splicing of its messenger RNA [16]. These
two forms have different effects on cell survival when
transfected into cells. Whereas the long form promotes
apoptosis, the short form acts as a dominant-negative
repressor of cell death. As with the ICE heterodimer, it is
thought that Ich-1s binds to Ich-1L, although direct
interaction has not been demonstrated. The ability of
Ich-1L to promote apoptosis provides additional evidence
for involvement of an ICE-like protease in controlling
the onset of apoptosis [16].
Death by proteolysis?
Major questions remain unanswered about the role of
ICE or an ICE-like homolog in initiation and/or
progression of apoptosis. First, is ICE (or a homolog)
responsible for direct activation of specific cellular
enzymes that subsequently cause the DNA cleavage,
membrane blebbing and/or volume changes often asso-
ciated with apoptosis? Alternatively, is apoptosis caused
by cleavage of other regulatory protein(s) that, in turn,
activate the enzymes required for progression of these
self-destructive cascades? These questions are worthy of
consideration and even speculation, since they can lead
to experimental hypotheses that can be tested, and may
provide further insight into these processes.
Recently, an ICE homolog now known as prICE was
shown to cleave poly(ADP-ribose) polymerase into an
active enzyme that causes oligonucleosomal laddering
and apoptosis-like morphology in a cell-free extract [15].
ICE is unable to substitute for prICE in this system,
although the two proteases share target substrate
sequence homologies. These data provide the first direct
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target sequence to ICE, although maybe not ICE itself,
in apoptotic processes.
If ICE, or a homolog, acts alone as the direct activator of
enzymes that participate in apoptosis, it seems necessary
to invoke the existence of a set of apoptotic enzymes that
have at least two common features: these target enzymes
must exist in precursor forms that are inactive until
cleaved, and these precursor proteins must share a
common protease recognition site. Although possible,
enzymes having diverse enzymatic activities while retain-
ing these common structural features are unlikely to have
survived evolution from the simplest multicellular organ-
isms to higher creatures. Alternatively, if ICE were mod-
ulating apoptosis through activation of other regulatory
enzymes, the cell death process could be further ampli-
fied. This latter situation seems more plausible. Together,
ICE and its activated substrate(s) could be responsible for
triggering numerous enzymatic cascades that lead to cell
death. This would place an ICE-like protease further
upstream in the process, giving it a more crucial role in
the initiation process. What remains unexplained by our
knowledge thus far, is what constitutes the ultimate
monitor that decides whether the cell should live or die.
If an ICE-like protease is the enzyme that triggers the
process of apoptosis, what controls the protease?
Numerous regulatory mechanisms have evolved for con-
trolling cellular processes. Often, these controls involve
chemical modification of pre-existing molecules within a
cell. This permits cellular control to be exerted in the
absence of de novo protein synthesis. Whereas proteolytic
cleavage of an inactive precursor would be an irreversible
event, phosphorylation represents perhaps the most com-
mon mechanism for rapid and reversible modulation of
cellular activities. Indeed, protein phosphorylation is an
essential component of many regulated cellular pathways,
including receptor-mediated signal transduction and cell
proliferation. Given the wide variety of kinases available
within a cell, and the requirement for activation of mul-
tiple enzymatic cascades during the program of apoptosis,
perhaps a combination of proteolytic events and chemical
modifications would propel the cell into apoptosis.
Phosphorylation is known to play a significant role in
controlling cell cycle progression [18,19]. A control
mechanism for apoptosis involving phosphorylation
might be expected, given the numerous parallel check-
points shared by apoptosis and the cell cycle.
Future directions
As noted at the outset, much remains to be discovered
before we will fully appreciate the processes that regulate
a cell's decision to live or to die. Understanding the role
of an ICE-like protease in the activation of its substrates
may provide further insights into the steps downstream of
this enzyme. Identification of factors that control ICE
activation may provide a view of the upstream parts of
this cascade. Clearly, the results of the last few years of
research in this area indicate that an ICE-like protease sits
at a pivotal point in the cascade leading to the cell death
process. Given the rapid progress that has been made in
this field, we certainly have entered a period that will be
known as 'the ICE age' in apoptosis research. It is only a
matter of time before we realize the full significance of
the role that this enzyme and its homologs play in cell
survival and cell death.
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